<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02809378</url>
  </required_header>
  <id_info>
    <org_study_id>MED-CT4-15-461</org_study_id>
    <nct_id>NCT02809378</nct_id>
  </id_info>
  <brief_title>The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of PONV</brief_title>
  <official_title>The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of Postoperative Nausea and Vomiting in the Women Patients Undergoing Thyroidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of postoperative nausea and vomiting (PONV) after thyroidectomy have been shown
      to be relatively high compared other surgeries, with a reported incidence 65-75 %. PONV may
      increase patient discomfort, delay patient discharge, and increase the cost of patient care,
      the risk of postoperative bleeding which may potentially cause airway obstruction.

      It is reported that the maintenance of anesthesia with propofol-remifentanil or
      sevoflurane-propofol-remifentanil decreased the incidence of PONV compared sevoflurane alone,
      but failed to demonstrate the decreased incidence of PONV in 6-24 hr postoperative period in
      patients undergoing thyroidectomy. Administration of Palonosetron, newly developed 5-HT3
      antagonists with long half life (48 hrs) may decrease the incidence of PONV particularly
      during this period.

      The purpose of this study was to evaluate and compare the incidence of PONV after
      thyroidectomy with three different anesthetic methods, sevoflurane or
      sevoflurane-propofol-remifentanil or sevoflurane-propofol-remifentanil-palonosetron in woman
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">April 20, 2017</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of postoperative nausea and vomiting</measure>
    <time_frame>24 hour postoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of postoperative nausea and vomiting</measure>
    <time_frame>at immediate postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of postoperative nausea and vomiting</measure>
    <time_frame>6 hour postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of postoperative nausea and vomiting</measure>
    <time_frame>48 hour postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>PONV</condition>
  <condition>Palonosetron</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anesthesia induction with pentothal sodium (4-5 mg/kg), maintenance with sevoflurane(1.6-2.5 vol%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane, remifentanil, and propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane, remifentanil, propofol, and palonosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction</description>
    <arm_group_label>Sevoflurane, remifentanil, propofol, and palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane</intervention_name>
    <description>Inhalational anesthetics Halogenated.</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_label>sevoflurane, remifentanil, and propofol</arm_group_label>
    <arm_group_label>Sevoflurane, remifentanil, propofol, and palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>ultra-short acting opioid anesthetics</description>
    <arm_group_label>sevoflurane, remifentanil, and propofol</arm_group_label>
    <arm_group_label>Sevoflurane, remifentanil, propofol, and palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentothal sodium</intervention_name>
    <description>intra-venous anesthetics for anesthesia induction</description>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>intra-venous anesthetics for anesthesia induction and maintenance</description>
    <arm_group_label>sevoflurane, remifentanil, and propofol</arm_group_label>
    <arm_group_label>Sevoflurane, remifentanil, propofol, and palonosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing thyroidectomy euthyroid status American Society of Anesthesiology
             Physical status 1,2

        Exclusion Criteria:

          -  Ideal body weight &gt;130% gastrointestinal disease prior administration of anti-emetics
             (24hr)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Hee Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou universiry hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>DAE HEE KIM</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Thiopental</mesh_term>
    <mesh_term>Anesthetics, Intravenous</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

